Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628591 | 0.88 | OPRM1 (0.55) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL21656684 | 0.87 | LMNA (0.64) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL19362910 | 0.86 | RAB9A (0.60) | RAB9APOLBMAPTLMNAL3MBTL1 | |
| SCHEMBL21628821 | 0.86 | LMNA (0.50) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL21628717 | 0.86 | LMNA (0.47) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL19363006 | 0.86 | PDE4B (0.53) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL21628553 | 0.86 | OPRM1 (0.54) | LMNAGRNSORT1OPRM1OPRD1 | |
| SCHEMBL19362917 | 0.83 | NPC1 (0.74) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL21656972 | 0.81 | MAPT (0.48) | RAB9ANPC1POLBCYP2C9MAPT | |
| SCHEMBL21656511 | 0.81 | MAPT (0.60) | MAPTL3MBTL1GRM2CYSLTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429576-B1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| WO-2017158190-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | NOTCH1, DNER, NOTCH4 | RAB9A 2237/4885NPC1 2328/4885POLB 1797/4885 |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | RAB9A 2207/4885NPC1 2429/4885POLB 1648/4885 |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | RAB9A 2237/4885NPC1 2328/4885POLB 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.